Max, I agree with you. What I think makes AD more difficult is that a lot of severe cases also suffer from other ailments which can complicate treatments. ie conflicts of a drug with another drug being taken that can together cause adverse effects.
The cost of care can vary significantly between a severe and moderate patients, so improvement to just the moderate level would be extremely valuable. It could be the difference between home care versus institutional care.
I agree with that. That's the thing with this drug, its so multi-modal. It's just hard to judge all that it really does do from phase 2 trials. Is the data specific enough to back up what we saw from multiple compassionate use patients as you say for an immediate benefit? I sure hope so. What about the genetic population such as Jenni with the PSEN1 issue? Those with potential APOE4 genetic damage that the Duke researchers wrote about? The drug has worked on so many levels in mice and in small numbers of patients so far. IMO we need a BP partner to push this forward more quickly and that's what I'm hoping we'll get with the data tomorrow or near term. JMHO
Market Data 
Markets 
AI
